Renephra secures six-figure funding from NorthInvest angels to advance clinical trials
A group of eight NorthInvest angels has backed the medical technology developer.
Share allotment filed at Companies House
Frontline medical professionals have created a device that enables home treatment for chronic fluid overload and conditions such as lymphoedema.
Renephra has secured a six-figure investment led by a group of eight NorthInvest angels, supported by prior backers including Catapult Ventures and the GM&C Life Sciences Fund. The funding will allow the company to conduct pilot clinical studies and advance its regulatory approval pathway.
Created by frontline clinicians, Renephra offers a home-based solution for patients suffering from chronic fluid overload and lymphoedema, aiming to reduce hospital admissions and improve quality of life. The current financing builds on previous support from regional funds and academic institutions as the company prepares its medical device for market entry.
From the founder
"Current treatments for these conditions require frequent hospitalisations for intravenous treatment with high doses of diuretics which is not only inconvenient for patients and associated with a risk of kidney injury but also costly. We offer a gentler, safer solution that can be delivered at home, offering patients better quality of life and reducing hospital admissions and costs to healthcare providers. This round of funding enables Renephra to carry out pilot clinical studies to demonstrate a viable success rate in target patients and to understand factors related to success. This is an essential next step for the company in advancing this much needed and promising technology through to regulatory approvals and making it available to clinicians and patients."
Idalia Dawidaska
MD at Renephra
Investor perspective
"Renephra are enabling innovative critical care which can not only ease suffering and improve the quality of life of those suffering from oedema, but possibly also has much wider applications."
Adam Beaumont
Founder, NorthInvest
Use of funds
- 01Fund research and development
